Form 8-K - Current report

ACADIA PHARMACEUTICALS INC false 0001070494 0001070494 2024-11-18 2024-11-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2024

 

 

Acadia Pharmaceuticals Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware		000-50768		06-1376651
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

12830 El Camino Real, Suite 400
San Diego, California		92130
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: [phone]

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ACAD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

---

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 18, 2024, Acadia Pharmaceuticals Inc. (the “Company”) agreed with Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial that he would be involuntarily terminated without Cause (as such term is defined in the Company’s Management Severance Benefit Plan (the “Severance Plan”)) from his position, effective immediately. Mr. Teehan will remain employed by the Company as a non-executive employee until December 31, 2024 to assist with the orderly transition of duties and responsibilities to a successor. Until a successor is appointed, Mr. Teehan’s responsibilities will be assumed by Catherine Owen Adams, the Company’s Chief Executive Officer, who has more than 30 years of commercial experience in the pharmaceutical industry.

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

						Acadia Pharmaceuticals Inc.
Date: November 20, 2024				By:		/s/ Jennifer J. Rhodes
						Jennifer J. Rhodes
						Executive Vice President, Chief Legal Officer & Secretary

Document and Entity Information	Nov. 18, 2024
Cover [Abstract]
Entity Registrant Name	ACADIA PHARMACEUTICALS INC
Amendment Flag	false
Entity Central Index Key	0001070494
Document Type	8-K
Document Period End Date	Nov. 18, 2024
Entity Incorporation State Country Code	DE
Entity File Number	000-50768
Entity Tax Identification Number	06-1376651
Entity Address, Address Line One	12830 El Camino Real
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92130
City Area Code	(858)
Local Phone Number	558-2871
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.0001 per share
Trading Symbol	ACAD
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

---